Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Psyence Biomedical Ltd. Common Shares (PBM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: PBM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 0.2% | Avg. Invested days 198 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.79M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 357553 | Beta -0.45 | 52 Weeks Range 0.58 - 108.00 | Updated Date 03/27/2025 |
52 Weeks Range 0.58 - 108.00 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -78.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -137.79% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3361580 | Price to Sales(TTM) - |
Enterprise Value 3361580 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 4527130 | Shares Floating 452803 |
Shares Outstanding 4527130 | Shares Floating 452803 | ||
Percent Insiders 2.41 | Percent Institutions 21.86 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Psyence Biomedical Ltd. Common Shares
Company Overview
History and Background
Psyence Biomedical Corp. focuses on the use of psychedelic medicine to treat psychological trauma and other mental health conditions. Founded relatively recently, it has focused on research, development, and potential commercialization of psilocybin-based treatments.
Core Business Areas
- Psychedelic Medicine Research and Development: Psyence engages in researching and developing psilocybin-based treatments for various mental health conditions. This includes pre-clinical and clinical trials.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its psilocybin-based therapies. Data from these trials is crucial for regulatory approvals.
Leadership and Structure
Details of Psyence's leadership structure were not available in the context given. Organizational structure typically involves a CEO, a board of directors, and various department heads managing research, development, and business operations.
Top Products and Market Share
Key Offerings
- Psilocybin-based Therapies (Developing): Psyence focuses on developing psilocybin-assisted therapies. This includes formulations, treatment protocols, and delivery methods. Market share is still emerging as these therapies await regulatory approval. Competitors: COMPASS Pathways (CMPS), Atai Life Sciences (ATAI).
Market Dynamics
Industry Overview
The psychedelic medicine industry is rapidly evolving, with increasing interest in using psychedelics, like psilocybin, for mental health treatments. Regulatory pathways are developing, and public perception is shifting. There are competitors in the early stages of developing drugs. Market conditions are volatile and speculative.
Positioning
Psyence is positioned as a research and development company focusing on psilocybin-based therapies. Its competitive advantage lies in its specific research programs and intellectual property. However, the company is relatively small compared to larger pharmaceutical companies entering the psychedelic space.
Total Addressable Market (TAM)
The global market for mental health treatments is estimated to be in the hundreds of billions of dollars. The TAM for psychedelic-assisted therapies is a subset of this, estimated to reach billions in the coming years as regulations evolve. Psyence's position relative to this TAM is as an early-stage player attempting to capture market share through successful trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Focus on psychedelic medicine research
- Intellectual property related to psilocybin therapies
- Participation in clinical trials
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on regulatory approvals
- Relatively small size and market presence
Opportunities
- Potential for breakthrough therapies for mental health conditions
- Growing acceptance of psychedelic medicine
- Partnerships with larger pharmaceutical companies
Threats
- Regulatory hurdles and uncertainties
- Competition from established pharmaceutical companies
- Negative public perception or safety concerns related to psychedelics
Competitors and Market Share
Key Competitors
- CMPS
- ATAI
Competitive Landscape
Psyence Biomedical lags established pharmaceuticals. Success hinges on novel discoveries, successful trials, and strategic partnerships. Competition will be fierce.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on the company's recent formation. The company has grown through its development of therapies and clinical trials.
Future Projections: Future projections are dependent on clinical trial outcomes and regulatory approvals. Analyst estimates would vary widely at this stage.
Recent Initiatives: Recent strategic initiatives include clinical trial advancements and potential partnerships.
Summary
Psyence Biomedical Corp is an early-stage company in the burgeoning psychedelic medicine field. The company is focused on developing psilocybin-based therapies, and is currently participating in clinical trials. While Psyence has the potential to discover break through therapies, it faces threats to its growth. Regulatory hurdles and competition from established pharmaceutical companies are key risks.
Similar Companies
- CMPS
- ATAI
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (when available)
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Psyence Biomedical Ltd. Common Shares
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2024-01-25 | CEO & Director Dr. Neil Maresky M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.psyencebiomed.com |
Full time employees - | Website https://www.psyencebiomed.com | ||
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.